Geneticists have discovered that a gene involved in the modification of ribonucleic acid is mutated in a significant proportion of people with a collection of blood cancers called myelodysplastic syndromes. The researchers found that mutations in the SF3B1 gene tended to be associated with a better prognosis, raising the possibility that patients could be screened for the mutation and their treatment tailored accordingly.